TransMedics Group (NASDAQ:TMDX) had its target price cut by stock analysts at Cowen from $40.00 to $28.00 in a report released on Thursday, The Fly reports. The brokerage currently has an “outperform” rating on the stock. Cowen’s target price would indicate a potential upside of 68.57% from the company’s previous close.
Separately, Zacks Investment Research raised TransMedics Group from a “sell” rating to a “hold” rating in a research note on Sunday, November 3rd. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $33.00.
NASDAQ TMDX traded down $0.64 during trading hours on Thursday, reaching $16.61. The stock had a trading volume of 196,200 shares, compared to its average volume of 89,326. The company’s fifty day moving average is $19.67. TransMedics Group has a 52-week low of $16.30 and a 52-week high of $31.54. The company has a quick ratio of 6.82, a current ratio of 7.55 and a debt-to-equity ratio of 0.48.
TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.39) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.47) by $0.08. The firm had revenue of $7.21 million during the quarter, compared to analyst estimates of $6.67 million. As a group, research analysts expect that TransMedics Group will post -2.25 earnings per share for the current year.
Institutional investors and hedge funds have recently modified their holdings of the business. NumerixS Investment Technologies Inc acquired a new stake in shares of TransMedics Group in the 2nd quarter worth $43,000. JPMorgan Chase & Co. acquired a new stake in shares of TransMedics Group in the 2nd quarter worth $50,000. Tower Research Capital LLC TRC acquired a new stake in shares of TransMedics Group in the 2nd quarter worth $190,000. Blackstone Group Inc acquired a new stake in shares of TransMedics Group in the 2nd quarter worth $290,000. Finally, Cubist Systematic Strategies LLC acquired a new stake in shares of TransMedics Group in the 2nd quarter worth $314,000. 65.88% of the stock is owned by institutional investors and hedge funds.
About TransMedics Group
TransMedics, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. The company offers Organ Care System (OCS), an integrated, compact, portable preservation technology that addresses unmet need for organs for transplantation.
Further Reading: Momentum Indicator: Relative Strength Index
Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter.